Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357638 | 0.93 | TLR7 (0.63) | TLR7 | |
| SCHEMBL4672516 | 0.92 | TLR7 (0.63) | TLR7 | |
| SCHEMBL13613797 | 0.92 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL29475743 | 0.92 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL5413811 | 0.91 | TLR8 (0.52) | TLR7TLR8 | |
| SCHEMBL5400851 | 0.89 | TLR8 (0.63) | TLR7TLR8 | |
| SCHEMBL6813136 | 0.86 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL676401 | 0.85 | TLR7 (0.60) | TLR7 | |
| SCHEMBL29852303 | 0.85 | TLR7 (0.60) | TLR7 | |
| SCHEMBL6031989 | 0.85 | TLR7 (0.60) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343784-B1 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS and pharmaceutical compositions comprising the same. | 3M INNOVATIVE PROPERTIES CO (US) | 2006-03-08 | — | — | EP | claimed |
| US-20040077678-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-22 | — | — | US | claimed |
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | claimed |
| US-6656938-B2 | Inducing cytokine biosynthesis in animals, for the treatment of diseases, including viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-02 | — | — | US | claimed |
| EP-1343784-A2 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS | 3M Innovative Properties Company (US) | 2003-09-17 | — | — | EP | claimed |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-21 | — | — | US | claimed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | claimed |
| WO-2002046191-A2 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | claimed |
| US-7612083-B2 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612083-B2 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612083-B2 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7214675-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214675-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214675-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-6660735-B2 | Inducing cytokine biosynthesis; viral diseases, neoplastic disorders | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-6656938-B2 | Inducing cytokine biosynthesis in animals, for the treatment of diseases, including viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-02 | — | — | US | disclosed |
| EP-1343784-A2 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS | 3M Innovative Properties Company (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-21 | — | — | US | disclosed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2002046191-A2 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885TLR8 273/4885 |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885TLR8 273/4885 |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885TLR8 273/4885 |
| US-20040077678-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885TLR8 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.